top of page
deliverysystem_vignette.jpg

Groundbreaking innovation

The SpyGlass Pharma™ Drug Delivery Platform combines safe, lasting treatment with the world's most common, routine ophthalmic surgery.

Spyglass Platform Pipeline

Spyglass-Platform-Pipeline-20250321_edit
texture_bg.jpg

SpyGlass Pharma Announces Positive 36-Month First-in-Human and 3-Month Phase I/II Trial Results for Its Novel BIM-IOL System

ALISO VIEJO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) --  SpyGlass Pharma™, a late-stage biopharmaceutical company, announces positive results from two clinical trials of its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for the treatment of elevated IOP in patients with mild-to-moderate open-angle glaucoma (OAG) or ocular hypertension (OHT). The data were presented by Malik Kahook, M.D., co-founder and president of SpyGlass Pharma, at the Interventional Glaucoma Consortium (IGC) in Salt Lake City, Utah on Saturday, November 8th, which included 36-month follow-up data from the FIH trial and three-month interim safety and efficacy results from the Phase I/II trial. (View full press release)

Spyglass Pharma Logo - Long - Black_edited.png

Technology

Tel: 949-284-6904

About

27061 Aliso Creek Rd, Suite 100
Aliso Viejo, CA 92656

Investors

CONTACT US

SUBSCRIBE

Sign up to receive SpyGlass Pharma™ news and updates.

Thanks for submitting!

© 2025 SpyGlass Pharma™. All Rights Reserved.

Follow us on LinkedIn

  • LinkedIn
bottom of page